Similar articles

• Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.

  Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK. Wilson HL, et al. Int Rev Immunol. 2006 May-Aug;25(3-4):183-213. doi: 10.1080/08830180600785868. Int Rev Immunol. 2006. PMID: 16818371 Review.
• CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.

  Jahrsdörfer B, Weiner GJ. Jahrsdörfer B, et al. Curr Opin Investig Drugs. 2003 Jun;4(6):686-90. Curr Opin Investig Drugs. 2003. PMID: 12901226 Review.
• CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.

  Harandi AM, Holmgren J. Harandi AM, et al. Curr Opin Investig Drugs. 2004 Feb;5(2):141-5. Curr Opin Investig Drugs. 2004. PMID: 15043387 Review.
• Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.

  Ishii KJ, Gursel I, Gursel M, Klinman DM. Ishii KJ, et al. Curr Opin Mol Ther. 2004 Apr;6(2):166-74. Curr Opin Mol Ther. 2004. PMID: 15195929
• CpG oligonucleotides as immune adjuvants.

  Krieg AM. Krieg AM. Ernst Schering Res Found Workshop. 2000;(30):105-18. doi: 10.1007/978-3-662-04183-3_7. Ernst Schering Res Found Workshop. 2000. PMID: 10943319 Review. No abstract available.